- PP405 - Wikipedia
Pelage Pharmaceuticals was named after the French word for "coat of fur" and PP405 was named after the company and the 405 freeway that goes through Los Angeles [2][8] The first human clinical trials of PP405 started in 2023 in Orange County [2][24]
- Pelage
PP405 targets stem cells to reawaken the dormant hair follicles and restore youthful appearance Also known as pattern hair loss, the most common type of hair loss in men and women Caused by a combination of genetics, hormones, age, and environmental factors
- PP405 Hair Loss Treatment: Trials, Mechanism Timeline
Learn what PP405 is, how it works for hair loss, clinical trial updates, expected release date, and how it compares to finasteride or minoxidil
- What is PP405: A Promising Hair Loss Solution—But Not Yet
Let’s explore what PP405 is, how it compares to existing treatments, and why hair transplantation remains the gold standard —especially for moderate to advanced hair loss What Is PP405? PP405 is a small molecule identified by UCLA researchers as a potential activator of dormant hair follicles
- Did UCLA Just Cure Baldness?
In the first human trials, conducted in 2023, researchers found that application of PP405 as a topical medicine onto the scalp at bedtime for a week produced promising results Although cautious with actual data, the UCLA researchers labeled the results “statistically significant ”
- Pelage Pharmaceuticals Phase 3 Trials for PP405 in 2026
Patent and technology rights to both topical drugs have been exclusively licensed to Pelage Pharmaceuticals by UCLA The hair loss drug that the company plans to release is called PP405, a topical inhibitor of the mitochondrial pyruvate carrier (MPC)
- Q A: Pelages Novel PP405 Advances to Phase 2a for . . .
Pelage Pharmaceuticals recently announced its novel topical agent, PP405, has advanced to a phase 2a study for androgenetic alopecia, with enrollment currently underway at sites across the US 1
- Did Scientists Just Cure Baldness? UCLA’s New Molecule Could . . .
UCLA scientists have developed a molecule, PP405, that may reverse hair loss by reactivating dormant follicles Early trials show promising results, and more testing is underway, with FDA approval still pending
|